Does measuring antibodies to infliximab help?
Antibodies to infliximab (ATIs) have been associated with loss of clinical response and lower serum infliximab (IFX) levels in some studies of patients with inflammatory bowel disease (IBD). Presumable lower levels mean less effectiveness, but it needs to be proven. It may be clinically useful to be able to assess and predict diminishing response. A recent meta-analysis of all available studies concluded that the presence of ATIs is associatedRead more